MODIFIED BLOOD SCREENING INSTRUMENT – eSAS 2 ADDENDUM AMENDING AGREEMENT ENTERED INTO AS OF JUNE 11, 1998 BY AND BETWEEN GEN-PROBE INCORPORATED, A DELAWARE CORPORATION AND CHIRON CORPORATION effective as of January 1, 2002Agreement • May 6th, 2005 • Chiron Corp • Pharmaceutical preparations
This Modified Blood Screening Instrument — eSAS 2 Addendum (“eSAS 2 Addendum”) is entered into, effective as of January 1, 2002 (“Addendum Effective Date”) pursuant to and amending that certain Agreement entered into as of June 11, 1998 (“Agreement”) by and between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation (“Chiron;” Chiron and Gen-Probe each is individually referred to as “Party” and collectively are referred to as the “Parties”) with a place of business at 4560 Horton Street, Emeryville, CA 94608.
AMENDMENT NO. 6 TO AGREEMENTAgreement • May 6th, 2005 • Chiron Corp • Pharmaceutical preparations
This Amendment No. 6 (“Amendment No. 6”) effective as of January 1, 2004 (the “Amendment Effective Date”) to that certain Agreement between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) and Chiron Corporation, a Delaware corporation (“Chiron”) dated as of June 11, 1998, as amended from time to time as of the Amendment Effective Date (the “Agreement”).
WITHOUT PREJUDICE AND SUBJECT TO CONTRACT COMPROMISE AGREEMENTCompromise Agreement • May 6th, 2005 • Chiron Corp • Pharmaceutical preparations • England and Wales
